Cargando…

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

BACKGROUND: In oncology clinical development, objective response rate, disease control rate and early tumor size changes are commonly used as efficacy metrics for early decision-making. However, for immunotherapy trials, it is unclear whether these early efficacy metrics are still predictive of long...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Meihua, Chen, Cong, Jemielita, Thomas, Anderson, James, Li, Xiaoyun (Nicole), Hu, Chen, Kang, S. Peter, Ibrahim, Nageatte, Ebbinghaus, Scot
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368769/
https://www.ncbi.nlm.nih.gov/pubmed/30736858
http://dx.doi.org/10.1186/s40425-019-0513-4
_version_ 1783394057482928128
author Wang, Meihua
Chen, Cong
Jemielita, Thomas
Anderson, James
Li, Xiaoyun (Nicole)
Hu, Chen
Kang, S. Peter
Ibrahim, Nageatte
Ebbinghaus, Scot
author_facet Wang, Meihua
Chen, Cong
Jemielita, Thomas
Anderson, James
Li, Xiaoyun (Nicole)
Hu, Chen
Kang, S. Peter
Ibrahim, Nageatte
Ebbinghaus, Scot
author_sort Wang, Meihua
collection PubMed
description BACKGROUND: In oncology clinical development, objective response rate, disease control rate and early tumor size changes are commonly used as efficacy metrics for early decision-making. However, for immunotherapy trials, it is unclear whether these early efficacy metrics are still predictive of long-term clinical benefit such as overall survival. The goal of this paper is to identify appropriate early efficacy metrics predictive of overall survival for immunotherapy trials. METHODS: Based on several checkpoint blockade based immunotherapy studies in metastatic melanoma, we evaluated the predictive value of early tumor size changes and RECIST-based efficacy metrics at various time points on overall survival. The cut-off values for tumor size changes to predict survival were explored via tree based recursive partitioning and validated by external data. Sensitivity analyses were performed for the cut-offs. RESULTS: The continuous tumor size change metric and RECIST-based trichotomized response metric at different landmark time points were found to be statistically significantly associated with overall survival. The predictive values were higher at Week 12 and 18 than those at Week 24. The percentage of tumor size changes appeared to have comparable or lower predictive values than the RECIST-based trichotomized metric, and a cut-off of approximately 10% tumor reduction appeared to be reasonable for predicting survival. CONCLUSIONS: An approximate 10% tumor reduction may be a reasonable cut-off for early decision-making while the RECIST-based efficacy metric remains the primary tool. Early landmark analysis is especially useful for decision making when accrual is fast. Composite response rate (utilizing different weights for PR/CR and SD) may be worth further investigation. TRIAL REGISTRATION: Clinical trials gov, NCT01295827, Registered February 15, 2011; NCT01704287, Registered October 11, 2012; NCT01866319, Registered May 31, 2013. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-019-0513-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6368769
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63687692019-02-15 Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma? Wang, Meihua Chen, Cong Jemielita, Thomas Anderson, James Li, Xiaoyun (Nicole) Hu, Chen Kang, S. Peter Ibrahim, Nageatte Ebbinghaus, Scot J Immunother Cancer Research Article BACKGROUND: In oncology clinical development, objective response rate, disease control rate and early tumor size changes are commonly used as efficacy metrics for early decision-making. However, for immunotherapy trials, it is unclear whether these early efficacy metrics are still predictive of long-term clinical benefit such as overall survival. The goal of this paper is to identify appropriate early efficacy metrics predictive of overall survival for immunotherapy trials. METHODS: Based on several checkpoint blockade based immunotherapy studies in metastatic melanoma, we evaluated the predictive value of early tumor size changes and RECIST-based efficacy metrics at various time points on overall survival. The cut-off values for tumor size changes to predict survival were explored via tree based recursive partitioning and validated by external data. Sensitivity analyses were performed for the cut-offs. RESULTS: The continuous tumor size change metric and RECIST-based trichotomized response metric at different landmark time points were found to be statistically significantly associated with overall survival. The predictive values were higher at Week 12 and 18 than those at Week 24. The percentage of tumor size changes appeared to have comparable or lower predictive values than the RECIST-based trichotomized metric, and a cut-off of approximately 10% tumor reduction appeared to be reasonable for predicting survival. CONCLUSIONS: An approximate 10% tumor reduction may be a reasonable cut-off for early decision-making while the RECIST-based efficacy metric remains the primary tool. Early landmark analysis is especially useful for decision making when accrual is fast. Composite response rate (utilizing different weights for PR/CR and SD) may be worth further investigation. TRIAL REGISTRATION: Clinical trials gov, NCT01295827, Registered February 15, 2011; NCT01704287, Registered October 11, 2012; NCT01866319, Registered May 31, 2013. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-019-0513-4) contains supplementary material, which is available to authorized users. BioMed Central 2019-02-08 /pmc/articles/PMC6368769/ /pubmed/30736858 http://dx.doi.org/10.1186/s40425-019-0513-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wang, Meihua
Chen, Cong
Jemielita, Thomas
Anderson, James
Li, Xiaoyun (Nicole)
Hu, Chen
Kang, S. Peter
Ibrahim, Nageatte
Ebbinghaus, Scot
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
title Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
title_full Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
title_fullStr Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
title_full_unstemmed Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
title_short Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
title_sort are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368769/
https://www.ncbi.nlm.nih.gov/pubmed/30736858
http://dx.doi.org/10.1186/s40425-019-0513-4
work_keys_str_mv AT wangmeihua aretumorsizechangespredictiveofsurvivalforcheckpointblockadebasedimmunotherapyinmetastaticmelanoma
AT chencong aretumorsizechangespredictiveofsurvivalforcheckpointblockadebasedimmunotherapyinmetastaticmelanoma
AT jemielitathomas aretumorsizechangespredictiveofsurvivalforcheckpointblockadebasedimmunotherapyinmetastaticmelanoma
AT andersonjames aretumorsizechangespredictiveofsurvivalforcheckpointblockadebasedimmunotherapyinmetastaticmelanoma
AT lixiaoyunnicole aretumorsizechangespredictiveofsurvivalforcheckpointblockadebasedimmunotherapyinmetastaticmelanoma
AT huchen aretumorsizechangespredictiveofsurvivalforcheckpointblockadebasedimmunotherapyinmetastaticmelanoma
AT kangspeter aretumorsizechangespredictiveofsurvivalforcheckpointblockadebasedimmunotherapyinmetastaticmelanoma
AT ibrahimnageatte aretumorsizechangespredictiveofsurvivalforcheckpointblockadebasedimmunotherapyinmetastaticmelanoma
AT ebbinghausscot aretumorsizechangespredictiveofsurvivalforcheckpointblockadebasedimmunotherapyinmetastaticmelanoma